DelveInsight's 2025 report reveals a robust pipeline with 75+ companies developing 80+ therapies for chronic kidney disease, highlighting significant industry investment in addressing this growing health concern.
The EASi-KIDNEY trial will assess vicadrostat's efficacy in slowing chronic kidney disease (CKD) progression when combined with existing treatments like empagliflozin.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.